ARCHIVES

IOM Recommends FDA Consolidate Each Drug’s Lifetime History

This article is from The Cancer Letter archive.

Vol. 38 No. 18 | May 4, 2012

Download PDF Visit The Full Archive

Related Articles

Phase III Study: Rituxan Improved PFS By 79% In Advanced Follicular Lymphoma

December 31, 2010

Virus Working Group Suggests 14 Projects As Suitable For New Contract Proposals

March 1, 1974

BRCA Mutations In About 2% Of Breast Cancer Patients

August 25, 2006

FDA Approves Rituxan For CLL

February 19, 2010

In Brief: Comprehensive Centers “Jewel In Crown” Of Cancer Program, DeVita Says; Boutwell New NCAB Member

February 18, 1983

Alimta Granted Approval As NSCLC Continuation Therapy

November 25, 2011